Providers are eager for the FDA to test integrating REMS requirements into electronic health records, but want the agency to ‘go slowly’ to avoid any disruptions along the way. Recent issues with two of the original restricted distribution plans in the US underscore the message of caution.
The US Food and Drug Administration is being urged to move cautiously as it rolls out new software to integrate Risk Evaluation and Mitigation Strategy activities into existing workflows for prescribers, payors and pharmacies.
During a meeting hosted by the Duke-Margolis Center for Health Policy earlier this month, panelists representing providers and patients stressed...
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
